Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Adlai Nortye licenses shelved Novartis compound buparlisib to develop combo cancer therapies

25 Oct 2021

Executive Summary

Adlai Nortye licensed exclusive worldwide development and commercialization rights to Novartis Pharma AG's buparlisib (BKM120) for all therapeutic, prophylactic, or diagnostic uses, except for certain rights Novartis retains.

Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Immuno-Oncology
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By